Abbreviations: AU, asymmetric unit; L-BE, Luciferin 6′-benzyl ether; L-CEE, Luciferin 6′-chloroethyl ether; L-H, 6′-deoxyluciferin; L-H-EGE, Ethylene glycol ester of L-H; L-ME, Luciferin 6′-methyl ether; L-ME-EGE, Ethylene glycol ester of L-ME; MES, 2-(N-morpholino) ethanesulfonic acid; PAGE, polyacrylamide gel electrophoresis; rmsd, root-mean-square deviations; SDS, sodium dodecyl sulfate; Tris, 2-amino-2-(hydroxymethyl)-1,3-propanediol. 
Introduction
Cytochrome P450 monooxygenases (P450s) are a superfamily of heme-containing enzymes that catalyze a wide variety of oxidative reactions, i.e., biosynthesis of steroid hormones, lipids, and complex antibiotics such as polyketides, detoxification of xenobiotics, drug metabolism, and bioconversion of recalcitrant molecules to utilize them as carbon sources [1] . Catalytic reactions include hydroxylation, epoxidation, phenol coupling, heteroatom oxidation, dehalogenation, and carbon-carbon bond cleavage via successive hydroxylations [2] . Functional studies of P450s have a major impact on human physiology; the catalytic abilities of P450s are highly attractive in that they involve a high regio-and stereo-selectivity, thus introducing the possibility of numerous biotechnological applications such as industrial production of valuable chemicals by bioconversion. To identify P450s with useful catalytic activities, we had previously developed a novel P450 expression system by using Escherichia coli that harbors a plasmid carrying both the P450 gene and feasible redox partner genes [3] . To date, we have collected 213 bacterial P450 genes and constructed an expression library for exploring useful P450s that facilitate the conversion to industrially valuable compounds. P450moxA from the rare actinomycete Nonomuraea recticatena IFO 14525 was first identified as an enzyme that exhinited ML236-B (compactin) hydroxylase activity. A sequence similarity search indicated that P450moxA belongs to the CYP105 family [4] . Recently, several CYP105 P450s have been characterized. P450sca-2 (CYP105A3) from Streptomyces carbophilus also possesses hydroxylation activity to ML236-B for its detoxification [5] . P450SU-1 (CYP105A1) from Streptomyces griseolus is known to metabolize sulfonylurea herbicides [6] and also convert vitamin D 3 to 25-hydroxyvitamin D 3 [7] . P450soy (CYP105D1) from Streptomyces griseus was found to be deeply involved in the degradation of a diverse array of complex agrochemicals and environmental pollutants [8, 9] . These observations clearly indicate that the CYP105 enzymes play a crucial role in xenobiotic degradation as well as antibiotic biosynthesis. Interestingly, tests for acceptable substrates have revealed that P450moxA also acts on a wide range of hydrophobic compounds such as testosterone [4] and oleanolic acid [10] . The remarkably broad substrate specificity of the CYP105 enzymes is reminiscent of the mammalian liver microsomal P450s, e.g., CYP2D6 and CYP3A4, which also exhibit broad substrate specificity for metabolizing a vast array of 4 xenobiotics (drugs) [11] . Most actinomycetes possess a relatively large number of P450s, including the CYP105s [12] , suggesting that they are important for survival in soil.
In this study, we demonstrate that P450moxA possesses the ability to act on certain luciferin derivatives, which were originally identified as substrates for the human liver microsomal P450s (CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, CYP3A7, and CYP2D6). Further, the crystal structure of P450moxA has been determined to a resolution of 2.8 Å in the substrate-free form. This is the first report of the X-ray structure of CYP105, and it may serve as a model for further structural study and molecular dynamics simulation analysis of CYP105 and related P450s.
Materials and methods

Plasmid construction and expression in Rhodococcus erythropolis.
Identification and cloning of the P450moxA gene (moxA) have been described previously [4] . The moxA gene and its downstream ferredoxin gene (moxB) were inserted into the pTipQT vector [13, 14] together with the R. erythropolis NI86/21 ferredoxin and ferredoxin reductase genes thcC and thcD [15] . A ribosome-binding site was added immediately upstream of thcCD in order to facilitate translation. The resulting plasmid pTipQT-MoxAB-ThcCD was introduced into the R. erythropolis JCM2301 cells by electropolation. For details, see Supplementary methods. P450 assay by the luminescent method. The P450 assay was performed using the P450-Glo TM assay system (Promega). Six luciferin derivatives, namely, luciferin
ethylene glycol ester of L-H (L-H-EGE), were tested as luminogenic substrates for the assay. The assays were performed according to the manufacturer's instructions. A reaction mixture prepared by mixing 35 μl of cell-free extracts (containing 300 μg of total proteins), 5 μl of 40 mM NADH, and 5 μl of each substrate (20-100 μM) was incubated for 6 hr at 30°C. Luminescence was measured using a luminometer (Centro LB 960; Berthold Technologies) after adding 40 μl of luciferin detection reagent to each reaction mixture.
X-ray structure analysis. Recombinant P450moxA with a His-tag at its C-terminus was overexpressed using E. coli, and the enzyme was purified by Ni-affinity .5-6% polyethylene glycol (PEG) 8000, and 15-20% glycerol. The X-ray diffraction data were measured at beamline BL6A of the Photon Factory (PF; Tsukuba, Japan). All the data were processed with the program MOSFLM [16] and SCALA [17] . The 6 structure of P450moxA was solved by the molecular replacement (MR) method using the program AMoRe [18] , applying the truncated structure of the P450eryF (CYP107A1; PDB code, 1jin) [19] as a search model. The program XtalView/Xfit [20] was employed for model building and fitting. Refinement was performed using the program CNS ver. 1.1 [21] . The data collection and refinement statistics are provided in 
Results and discussion
P450 assay with 6 luminogenic substrates
Successful coexpression of P450moxA and the feasible redox partner ThcCD in R. erythropolis was induced by thiostrepton ( Fig. 1(A) ). The cell-free extracts were tested for P450-Glo TM assay system (Promega) [22] by using the 6 available luminogenic substrates. The results clearly indicated that P450moxA possessed activity for the 4 substrates L-CEE, L-ME, L-BE, and L-ME-EGE, which were originally identified as substrates for the human microsomal P450s, namely, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2D6, CYP3A4, and CYP3A7. In contrast, no activity was detected for L-H and L-H-EGE ( Fig. 1(B) ). The catalytic reactions in this assay were not simple hydroxyl group insertions to the substrates as observed for many bacterial P450s but were the following elimination reactions: dechloroethylation of L-CEE, demethylation of L-ME and L-ME-EGE, and debenzylation of L-BE. Such cleavage activity was not very common in both prokaryotic and eukaryotic P450s [23] and have not been reported in the case of the CYP105 enzymes thus far. The debenzylation activity of L-BE is particularly interesting because the enzyme eliminated the relatively bulky benzyl group. This implied that a large hydrophobic cavity is created in the proximity of the heme, which might enable capture of a wide range of compounds at the substrate binding site.
Crystal structure of P450moxA
The crystal structure of P450moxA was determined using the MR method and refined at a resolution of 2.8 Å with reasonable stereochemical quality. The crystallographic R-factor (R work ) and R-free factor (R free ) converged to 23.0% and 27.4%, respectively. The AU contains 2 P450moxA molecules (chains A and B) with a solvent content, 62.2%. No conformational differences were observed between these 2 chains in the AU; the root-mean-square deviation (rmsd) for the main chain atoms (residues 10-412) was 0.27 Å. The overall structure of the P450moxA exhibits a typical P450 fold, as illustrated in Fig. 2 (A). The molecule is described to be triangular in shape with 55-Å long sides and of 30-Å thick. The structure comprises 14 α-helices (αA-αL, αB´and αK´) and 6 β-strands (β1-β6), and it is roughly divided into α-rich and β-rich regions.
The most distinguishing feature of the P450 fold is an I-helix with a length of almost 50
Å that runs across the entire molecule. The heme is embedded in the proximal I-helix and distal L-helix, and the Cys356 derived from the N-terminal of the L-helix serves as the fifth axial thiolate ligand to the heme iron. The molecules have a well-defined electron density map except for N-terminal 8 residues in chain A, 7 residues in chain B, and for C-terminal 1 residue in both the chains; the models for these could not be established. Electron density for 5 of the 6 histidine residues (residues 408-412) at the C-terminal His-tag sequence was clearly observed due to the presence of the metal ion detected in the mFo − DFc map with approximately 11.0 σ level. The metal is coordinated in a tetrahedral geometry by side-chains of His410, His412, His132´ and Asp136´ (prime sign indicates the residues belonging to other molecules in the AU). A database search for the metal coordination groups [24] suggested that the bound metal was most probably Fe. The crystallization mother liquor contained no heavy metals such as Zn, Fe, or Cu, and it is likely that Fe originated as a result of the degradation of the heme in the crystallization droplets during prolonged storage. Additionally, the MES molecules were found to bind to the substrate-binding site (see the substrate-binding site).
Structural comparison with other known P450s
The phylogenetic tree reveals that CYP105 is closely related to the CYP55 and CYP107. This evolutionary relationship is consistent with the results of the 3D structure superimpositions, as shown in Fig. 2 (B) . The pairwise structure comparison utilizing the DALI server [25] demonstrates that P450moxA is the most structurally homologous to the fungal nitric oxide reductase P450nor (CYP55A1 [26] [27] [28] ) (PDB code, 1ROM; Z score, 52.6; rmsd, 1.7 Å for 393 Cα atoms; sequence identity for fit regions, 37%). Here, the notable finding was that despite the functional differences between P450moxA and P450nor, the main-chain structure, including the BC-loop and FG-helices, was very similar to each other. P450nor accommodates NADH at the substrate-binding pocket that enables direct hydride transfer to the NO-bound heme, and the 2 arginine residues (Arg64 at the F-helix and Arg174 at the BC-loop) are considered to be important for the binding of the pyrophosphate moiety of the bound NADH [28] . Additionally, P450nor
comprises the unique residues Ser286 and Asp393 that form the proton delivery pathway [26, 27] . In contrast, the P450moxA possesses a highly hydrophobic substrate-binding pocket and possesses no such residues, suggesting a considerable functional divergence (Fig. 3) . P450moxA can also be well superimposed on the substrate-free open form of the P450 PikC (CYP107L1 [29] ) (PDB code, 2BJV chain B;
Z score, 46.5; rmsd, 2.2 Å for 378 Cα atoms; sequence identity for fit regions, 39%).
The substrate-free (open) and substrate-bound (close) forms of the PikC structure were investigated, and it was revealed that binding of the bulky substrate narbomycin or YC-17 causes repositioning of the BC-loop and FG-helices [29] . Movement of the BC-loop and FG-helices is often observed in the P450 structure, and P450moxA might thus have a potential for such conformational changes when the substrate is bound. We also compared the structure of P450moxA with that of the human microsomal P450s CYP1A2 (PDB code, 2hi4), CYP2C8 (1pq2) [30] , CYP3A4 (1tqn) [31] and CYP2D6 (2f9q) [32] . Although the overall structure of these P450s is primarily similar (Z score, ~30.0), the low sequence identity (~18%) with ubiquitous sequence gaps results in a mutual conformational distortion of the P450 fold. Therefore, the substrate-binding sites of P450moxA and the microsomal P450s are not correctly superimposed. This indicates that the shared enzymatic properties of both types of P450s might have been acquired convergently.
Substrate binding site
The convincing electron density map enabled construction of the continuous model from the N-terminus to the C-terminus, and the structure of the substrate-binding pocket is well defined. The pocket above the heme is formed by the side-chains of Thr79, Leu80, Thr84, Leu88, Leu94, Leu96, Val295, Val396, and Ile397. The hydrophobic property of the substrate-binding pocket agrees with the substrate specificity of P450moxA, i.e., the P450moxA prefers highly hydrophobic compounds such as oleanolic acid and testosterone as substrates. In contrast, most of the hydrophobic residues of P450moxA are conserved neither in P450nor nor in the other known CYP105 P450s (Fig. 3) . The crystal structures of P450nor reveal that the corresponding site comprises several hydrophilic side chains such as Arg64 and Arg174, which might play an important role in NADH recognition (Fig. 3 ).
As described above, P450moxA exhibits reasonable debenzylation activity with regard to L-BE. The reaction entails the simultaneous occupation of the benzyl group and luciferin moiety of L-BE adjacent to the heme iron, and thus, it requires a large space proximal to the heme. In the current structure, such a space is observed to be surrounded by the I-helix, Leu94, Leu96, Ala292, Val295, and Ile397. However, some of the P450s show a similar large space proximal to the heme, particularly in the substrate-free open form, despite lacking ability to act on bulky compounds. It is clear that, in order to understand the substrate recognition mechanism of P450s, the substrate complex structures need to be determined.
Unexpectedly, the current structure analysis reveals that the MES molecule occupies the substrate-binding site (Fig. 4 ). Model refinement indicates that although the average B-factor is high, MES is bound at the substrate-binding site with full P450moxA have also been shown. The alignment was performed using CLUSTALW [33] . Identical, strongly similar, and weakly similar residues are denoted by asterisks, colons, and dots, respectively. 
Supplementary methods
Plasmid construction and expression in Rhodococcus erythropolis.
Identification and cloning of the P450moxA gene (moxA) have been described previously [1] . The moxA gene and its downstream ferredoxin gene (moxB) were inserted into the pTipQT vector [2, 3] together with the R. erythropolis NI86/21
ferredoxin and ferredoxin reductase genes thcC and thcD [4] . A ribosome-binding site (RBS) was added immediately upstream of thcCD in order to facilitate translation. The resulting plasmid pTipQT-MoxAB-ThcCD was introduced into the R. erythropolis JCM2301 cells by electropolation. The transformed cells were grown at 30°C in 100 ml of Luria-Bertani (LB) medium containing 20 μg/ml tetracycline. The preculture was then inoculated into 1000 ml of LB medium supplemented with 1 μg/ml thiostrepton for 24 hr at 30°C to induce expression of MoxAB and ThcCD. The cells were harvested and resuspended in buffer containing 50 mM Tris-HCl (pH 7.4), 10% glycerol and 1 mM dithiothreitol (DTT). Cell lysis was performed using sonication, and the homogenate was clarified by centrifugation. Glycerol was added to the cell-free extracts to a final concentration of 20%. The quantity of the expressed proteins was verified using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and the Bradford protein assay (Bio-Rad).
Overexpression in E. coli and purification. For the X-ray structure analysis, a large amount of recombinant P450moxA was produced using E. coli as the expression host. The gene encoding P450moxA (moxA) was amplified using polymerase chain reaction (PCR) with the following oligonucleotide primers incorporating the NdeI and SpeI sites (underlined) and C-terminal His-tag sequence: moxA-forward (NdeI) 5'-GCC CCC CAT ATG ACG AAG AAC GTC GCC GAC-3' and moxA-His 6 -reverse Electronic Supplementary Material (online publication only) Click here to download Electronic Supplementary Material (online publication only): Supplementary_methods.doc (SpeI) 5'-GCC ACT AGT TCA GTG GTG GTG GTG GTG GTG CCA GGT GAC CGG GAG TTC GTG-3'. The amplified fragments were purified, digested with NdeI and SpeI, and cloned into the NdeI/SpeI sites of pT7NS-camAB [5] . The expression vector was transformed into the E. coli BL21 (DE3) strain. The cells were grown at 37°C for 3hr, and ethanol and glycerol were then added to 3% and 0.8%, respectively, to the culture medium for enhanced folding of P450moxA [6] . Overexpression was induced at 22°C for 22 hr by the addition of 0.1 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) to the culture medium supplemented with 80 μg/ml δ-aminolevulinic acid. The cells were harvested by centrifugation and resuspended in buffer A (50 mM Tris, pH 7.5, 10% glycerol, 2 mM DTT). Lysozyme was added to a final concentration of 2 mg/ml, and the suspension was maintained on ice for 30 min. Subsequently, the cells were disrupted by sonication, and the insoluble debris was separated by centrifugation. The supernatant was dialyzed against Buffer B (50 mM Tris, pH 7.5, 10% glycerol, 10 mM imidazol). The sample was then applied to a Ni-NTA resin (QIAGEN), which had been pre-equilibrated with buffer B. The column was washed with buffer B, and the enzyme was eluted using a linear gradient of 10-400 mM imidazol in buffer B. The fractions were analyzed using SDS-PAGE. Peak fractions were pooled, dialyzed against a buffer containing 20 mM Tris pH 7.5, 10% glycerol and 50 mM NaCl, and were concentrated to 20 mg/ml, by using a centrifugal filtration device (Millipore). The CO difference spectral assay was performed to verify that the purified P450moxA was in an active form [7] . The sample was stocked at -80°C until use for crystallization.
Crystallization. Prior to crystallization, the glycerol was removed from the sample, and the protein concentration was adjusted to 8.0 mg/ml based on the results of Structure determination and refinement. The X-ray diffraction data were measured under cryogenic conditions (100 K) at beamline BL6A of the Photon Factory (PF; Tsukuba, Japan). All the diffraction spots were indexed and integrated with the program MOSFLM [8] , and data scaling and merging were performed using the program SCALA [9] . The structure of P450moxA was solved by the molecular replacement (MR) method using the program AMoRe [10] , applying the truncated structure of the P450eryF (CYP107A1; PDB code, 1jin) [11] as a search model. The MR solutions obtained revealed 2 molecules of P450moxA in the asymmetric unit (AU). The phase bias caused by the search model was reduced by density modification (solvent flattening, non-crystallographic symmetry (NCS) averaging, and histogram matching) by using the program DM [12] . The program XtalView/Xfit [13] was employed for model building and fitting. Atomic coordinates and isotropic B-factor refinement were performed using the program CNS ver. 1.1 [14] by applying the NCS restraint for the main-chain atoms (residues 15-74, 80-183, 197-339). The topology and parameter files for the bound ligands were obtained from the hic-up web site (http://xray.bmc.uu.se/hicup/) [15] . The stereochemical quality of the final refined model was verified by the program PROCHECK [16] . The data collection and refinement statistics are provided in Table 1 .
The atomic coordinates and structure factor amplitudes for P450moxA were deposited in the RCSB Protein Data Bank (http://www.rcsb.org) under accession code 2z36.
Molecular illustrations (Figs 2 and 4) were prepared using the program PyMOL [17] . 
